The state of publicly traded biotech firms.
The biotechnology industry performed well in 2008 despite the worldwide economic downturn, but financial services firm Ernst & Young warns that the industry has to find new ways to do business. Revenues of publicly traded biotech companies rose by an average of 12% worldwide in 2008. But capital raised in Europe and the Americas was down by almost half from 2007, and funds raised through initial public offerings fell by 95% for the period (see Nature 458, 1062; 2009). “Firms will need to establish more durable models for funding innovation,” says Glen Giovannetti, Ernst & Young's global biotechnology leader, on the company's website.
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Biotech funding rethink. Nature 459, 467 (2009). https://doi.org/10.1038/nj7245-467e
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7245-467e